Two oral presentations, two poster discussion presentations, three poster
SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ --
Exelixis, Inc. (Nasdaq: EXEL) announced today that data from clinical
trials of the company's investigational compounds XL647, XL184, XL765 and
XL880 will be presented at the 2008 American Society of Clinical Oncology
(ASCO) Annual Meeting, which will be held from May 30 to June 3, 2008 in
Chicago, Illinois. The clinical trial data will be described in two oral
presentations (XL184 and XL765), two poster presentations and discussions
(XL647), and three poster presentations (XL647 and XL880).
-- XL184 (RET, MET, VEGFR2). Data from a phase 1 trial of XL184 in
patients with advanced malignancies, including medullary thyroid
cancer, will be presented on Sunday, June 1, 2008, starting at 10 a.m.
local time (Abstract #3522).
-- XL765 (PI3K, mTOR). Data from a phase 1 trial of XL765 in patients
with advanced solid tumors will be presented on Saturday, May 31,
2008, starting at 1:15 p.m. local time (Abstract #3510).
Poster Presentations and Discussions
-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in
NSCLC patients with acquired resistance to EGFR tyrosine kinase
inhibitors will be presented on Monday, June 2, 2008, during the 8
a.m.-noon session (Abstract #8028).
-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 1 trial of XL647 dosed
daily in patients with advanced solid malignancies will be presented
on Saturday, May 31, 2008, during the 8 a.m.-noon session (Abstract
|SOURCE Exelixis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved